Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.

[1]  F. Zoulim,et al.  Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance , 1999, Hepatology.

[2]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[3]  Y. Cheng,et al.  Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.

[4]  R. D. de Man,et al.  Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. , 1998, The Journal of infectious diseases.

[5]  R. Liang,et al.  Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. , 1998, Journal of hepatology.

[6]  J. Wands,et al.  Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.

[7]  K. Korn,et al.  Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. , 1997, Transplantation.

[8]  R. D. de Man,et al.  Lamivudine resistance inimmunocompetent chronic hepatitis B , 1997 .

[9]  S. Locarnini,et al.  Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro , 1997, Hepatology.

[10]  I. Marino,et al.  Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. , 1997, Transplantation.

[11]  P. Angus,et al.  Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. , 1997, Journal of hepatology.

[12]  G. Pape,et al.  Role for CD4 positive T cell response in the pathogenesis of hepatitis B. , 1997, Journal of hepatology.

[13]  R. Lanford,et al.  Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase , 1997, Journal of virology.

[14]  F. Zoulim,et al.  Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription , 1997 .

[15]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.

[16]  A. Burroughs,et al.  Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis , 1996, The Lancet.

[17]  T. Shaw,et al.  Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir , 1996, Hepatology.

[18]  R. Tubiana,et al.  Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men , 1996, Annals of Internal Medicine.

[19]  D. Tyrrell,et al.  Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.

[20]  E. Elias,et al.  Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine , 1996, Hepatology.

[21]  T. Berg,et al.  Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[22]  D. Tyrrell,et al.  Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro , 1996, Antimicrobial agents and chemotherapy.

[23]  M. Manns,et al.  Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. , 1996, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  H. Thomas,et al.  A double blind, placebo‐controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection , 1996, Journal of viral hepatitis.

[25]  B. Korba,et al.  Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells , 1996, Antimicrobial agents and chemotherapy.

[26]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[27]  D. Tyrrell,et al.  Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine , 1995, Antimicrobial agents and chemotherapy.

[28]  M. Manns,et al.  Prostaglandin E plus famciclovir--a new concept for the treatment of severe hepatitis B after liver transplantation. , 1994, Transplantation.

[29]  S. Locarnini,et al.  In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus , 1994, Antimicrobial Agents and Chemotherapy.

[30]  F. Zoulim,et al.  Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase , 1994, Journal of virology.

[31]  R. Hodge.  Famciclovir and Penciclovir. The Mode of Action of Famciclovir Including Its Conversion to Penciclovir , 1993 .

[32]  D. Earnshaw,et al.  Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus , 1992, Antimicrobial Agents and Chemotherapy.

[33]  R. Schinazi,et al.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Radziwill,et al.  Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity , 1990, Journal of virology.

[35]  I Sauvaget,et al.  Identification of four conserved motifs among the RNA‐dependent polymerase encoding elements. , 1989, The EMBO journal.